TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Benzinga Logo Benzinga By Vandana Singh
Novartis Maintains Outlook Even As Generics Bite Into Profits

Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.

Insights
NVS   neutral

Mixed performance with sales growth offset by generic competition, maintained full-year guidance, and strategic acquisition